Recombinant EPH Receptor A2 anticorps (AA 25-534)

N° du produit ABIN7452579

Cet anticorps anti-EPH Receptor A2 est un anticorps Lapin Monoclonal détectant EPH Receptor A2 dans WB et IP. Adapté pour Humain.

Aperçu rapide pour Recombinant EPH Receptor A2 anticorps (AA 25-534) (ABIN7452579)

Antigène: EPH Receptor A2 (EPHA2)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Cet anticorp EPH Receptor A2 est non-conjugé

Application: Western Blotting (WB), Immunoprecipitation (IP)

Clone: BLR136H

Détail du produit anti-EPH Receptor A2 anticorps

Épitope: AA 25-534

Fonction: Rabbit anti-EphA2 Recombinant Monoclonal Antibody [BLR136H]

Immunogène: residues 25-534 (ECD)

Isotype: IgG

Information d'application

Indications d'application:

IP: 20 μL/1 mg lysate

WB: 01:01,00

Restrictions: For Research Use only

Stockage

Concentration: 40 μg/mL

Buffer: Borate Buffered Saline (BBS) pH 8.2 with 0.1 % BSA and 0.09 % Sodium Azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Date de péremption: 12 months

Détails sur EPH Receptor A2

Antigène: EPH Receptor A2 (EPHA2)

Autre désignation: EphA2

Sujet: Background: Ephrin type-A receptor 2 (EphA2) is a member of the Eph family of tyrosine kinase receptors. Eph receptors have been shown to play a critical role in the development of the nervous system, where they regulate patterning during neural development. The ligands for Eph receptors are ephrins. Ephrin receptors and ligands have been found to be frequently overexpressed in a wide variety of cancers. Contrary to the usual finding that the oncogenic properties of tyrosine kinase receptors are promoted by the autophosphorylation of the receptor, it is the dephosphorylation of EphA2 that is associated with its oncogenic activity. The major study of EphA2 has been in relation to its contribution to malignancy and the possibility of targeting it in cancer therapy.

ID gène: 1969

NCBI Accession: NP_004422

UniProt: P29317

Pathways: Signalisation RTK